0001209191-17-019994.txt : 20170310
0001209191-17-019994.hdr.sgml : 20170310
20170310200532
ACCESSION NUMBER: 0001209191-17-019994
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170309
FILED AS OF DATE: 20170310
DATE AS OF CHANGE: 20170310
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADURO BIOTECH, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
BUSINESS PHONE: 510-848-4400
MAIL ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brockstedt Dirk G.
CENTRAL INDEX KEY: 0001635616
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 17683559
MAIL ADDRESS:
STREET 1: C/O ADURO BIOTECH, INC.
STREET 2: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-03-09
0
0001435049
ADURO BIOTECH, INC.
ADRO
0001635616
Brockstedt Dirk G.
C/O ADURO BIOTECH, INC.
740 HEINZ AVENUE
BERKELEY
CA
94710
0
1
0
0
EVP of Research and Dev.
Common Stock
2017-03-09
4
M
0
8000
0.45
A
57300
D
Common Stock
2017-03-09
4
S
0
8000
11.0001
D
49300
D
Stock Option (Right to Buy)
0.45
2017-03-09
4
M
0
8000
0.00
D
2020-03-18
Common Stock
8000
35195
D
The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.85 to $11.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The shares subject to the Option are fully vested and immediately exercisable.
/s/ Jennifer Lew, Attorney-in-Fact
2017-03-10